The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Melatonin exerts its actions through membrane MT1/MT2 melatonin receptors, which belong to the super family of G-protein-coupled receptors consisting of the typical seven transmembrane domains. MT1 and MT2 receptors are expressed in various tissues of the body either as single ones or together. A growing literature suggests that the melatonergic system may be involved in the pathophysiology of mood and anxiety disorders. In fact, some core symptoms of depression show disturbance of the circadian rhythm in their clinical expression, such as diurnal mood and other symptomatic variation, or are closely linked to circadian system functioning, such as sleep-wake cycle alterations. In addition, alterations have been described in the circadian rhythms of several biological markers in depressed patients. Therefore, there is interest in developing antidepressants that have a chronobiotic effect (i.e., treatment of circadian rhythm disorders). As melatonin produces chronobiotic effects, efforts have been aimed at developing agomelatine, an antidepressant with melatonin agonist activity. The present paper reviews the role of the melatonergic system in the pathophysiology of mood and anxiety disorders and the clinical characteristics of agomelatine. Implications of agomelatine in “real world” clinical practice will be also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630
Pineal Melatonin: Cell Biology of Its Synthesis and of Its Physiological Interactions*
REITER, R. J. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-2-151 · Cited by 2,192
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 2×
“In addition to high response rates, two studies reported that the differences in antidepressant efficacy were not statistically significant when comparing agomelatine with venlafaxine or paroxetine [117,119].”
BackgroundResultMelatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Self-citationThe Neural Correlates of Anhedonia in Major Depressive Disorder
Keedwell, P. A., Andrew, C., Williams, S. C. R., Brammer, M. J., & Phillips, M. L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.019 · Cited by 650 · cited 1×
“considered a core symptom of MDD, a predictor of poor outcome [134], a common residual symptom after treatment [135] and associated with dysfunctions within the brain reward system [136,137].”
BackgroundModulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions
Di Chiara, G., Morelli, M., & Consolo, S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90005-1 · Cited by 467 · cited 1×
“Moreover, it has been demonstrated that melatonin may directly reduce NMDA glutamate receptor functions in striatal neurons, thereby reducing NMDA-mediated long-term synaptic responses in this brain region [73].”
BackgroundGoodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Meyer-Bernstein, E., & Morin, L. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02097.1996 · Cited by 312 · cited 1×
“Substantially, serotonin may act as a synchronizer with the same effects as light on SCN neurons [48].”
BackgroundMartinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d6c25 · Cited by 276
Self-citationMontgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Leproult, R., Van Onderbergen, A., L’Hermite‐Balériaux, M., Van Cauter, E., & Copinschi, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02341.x · Cited by 167 · cited 1×
“The accelerating effect of agomelatine was particularly notable if treatment was started three weeks prior to the induced phase shift [89,90].”
BackgroundInteractions of the serotonin and circadian systems: nature and nurture in rhythms and blues
Ciarleglio, C. M., Resuehr, H. E. S., & McMahon, D. G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.036 · Cited by 151 · cited 1×
“downward trend during the night and an upward increase in the daytime [54].”
BackgroundQuera-Salva, M.-A., Hajak, G., Philip, P., Montplaisir, J., Keufer-Le Gall, S., Laredo, J., & Guilleminault, C. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328349b117 · Cited by 91
Self-citationRole of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Self-citationNew light on the serotonergic paradox in the rat circadian system
Cuesta, M., Clesse, D., Pévet, P., & Challet, E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06128.x · Cited by 67 · cited 1×
“studies demonstrated that the reasons for this “paradox” reside in the light/dark-dependent differential expression of serotonergic-specific receptors in the SCN [53].”
Background
Cited by
Dong, Y., Fan, C., Hu, W., Jiang, S., Ma, Z., Yan, X., Deng, C., Di, S., Xin, Z., Wu, G., et al. (2016) · Journal of Pineal Research · doi:10.1111/jpi.12300 · Cited by 170
“) [15, 16], cognitive disorders [17, 18], learning and memory impairments [19], and anxiety disorders [20].”
BackgroundTreating Circadian Rhythm Disruption in Bipolar Disorder
Gold, A. K., & Kinrys, G. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1001-8 · Cited by 102
Update of sleep alterations in depression.
Medina, A. B., Lechuga, D. A., Escandón, O. S., & Moctezuma, J. V. (2014) · Sleep Science · doi:10.1016/j.slsci.2014.09.015 · Cited by 65
Agomelatine for the treatment of generalized anxiety disorder
Buoli, M., Grassi, S., Serati, M., & Altamura, A. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359257 · Cited by 61
Cubero-Millán, I., Molina-Carballo, A., Machado-Casas, I., Fernández-López, L., Martínez-Serrano, S., Tortosa-Pinto, P., Ruiz-López, A., Luna-del-Castillo, J.-D.-D., Uberos, J., & Muñoz-Hoyos, A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150917115 · Cited by 19
“A hypothetical link between these comorbidities may be the dysregulation of biological rhythms due to alterations in the melatoninergic system [17,18].”
Background
Metadata
- Authors
- De Berardis, D., Marini, S., Fornaro, M., Srinivasan, V., Iasevoli, F., Tomasetti, C., Valchera, A., Perna, G., Quera-Salva, M.-A., Martinotti, G., & Di Giannantonio, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-06-13
- Volume
- 14
- Issue
- 6
- Pages
- 12458-12483
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2163413605
- Cited by
- 83
- References
- 15
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.